After NICE rejected Novartis’ migraine prevention drug Aimovig in draft guidance issued in January, it was inundated with comments that forced a delay to its final appraisal document.

UnitedHealth Group's pharmacy benefit manager, Optum Rx, said on Wednesday it would ease requirements to get insurance ...

But few treatment options exist. Pharmaceutical firms Amgen and Novartis are seeking to change that with Aimovig, which in May became the first Food and Drug Administration–approved drug ...

The FDA has approved the first in a new class of migraine drugs, Novartis and Amgen’s Aimovig, and at a lower than expected list price of $6,900. Aimovig’s price in is almost $575 a month ...